2004
DOI: 10.1007/s00125-004-1495-3
|View full text |Cite
|
Sign up to set email alerts
|

Conformation-dependent GAD65 autoantibodies in diabetes

Abstract: Aims/hypothesis. Conformation-dependent autoantibodies directed against GAD65 are markers of Type 1 diabetes. In this study we aimed to determine whether the substitution of GAD65 with GAD67 amino acids would affect the binding of conformation-dependent GAD65 autoantibodies. Methods. We used PCR-based site-directed mutagenesis to generate a series of mutated GAD65 cDNA constructs in which specific GAD65 coding sequences for regions of the protein critical for autoantibody binding were replaced with GAD67 codin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2005
2005
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 49 publications
(70 reference statements)
0
4
0
Order By: Relevance
“…Thus, it remains to be determined whether these peptides represent natural epitopes related to SPS or alternatively T1D. A few studies describe that the major epitopes of GAD67 appears to be conformational, similar to the major epitopes of GAD65 . Thus, identification of these N ‐terminal continuous epitopes of GAD67 may be valuable in relation to development of potential therapeutic reagents.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Thus, it remains to be determined whether these peptides represent natural epitopes related to SPS or alternatively T1D. A few studies describe that the major epitopes of GAD67 appears to be conformational, similar to the major epitopes of GAD65 . Thus, identification of these N ‐terminal continuous epitopes of GAD67 may be valuable in relation to development of potential therapeutic reagents.…”
Section: Discussionmentioning
confidence: 99%
“…Analysis of GAD autoantibodies in SPS and T1D has shown similarities and differences in relation to antigen recognition . In both diseases, GAD antibody reactivity is predominantly directed to conformational epitope regions in the middle and the C ‐terminal domains of GAD65 (amino acids 242–439 and 450–585) . Additionally in SPS, there is reactivity to conformational epitopes on GAD67 , and short linear epitopes in the C ‐terminal region and in the N ‐terminus of GAD65 .…”
Section: Introductionmentioning
confidence: 99%
“…The two isoforms are divided into three functional domains, an amino-terminal domain, a middle domain where the catalytic site resides (PLP-binding domain), and a carboxy-terminal domain. Roughly, antibodies to GAD67 are primarily associated with stiff-person syndrome (SPS) and autoimmune polyendocrine syndrome type 1, whereas GAD65 is a dominant autoantigen in type 1 diabetes (T1D) [2,24,25,26,27,28,29].…”
Section: Introductionmentioning
confidence: 99%
“…The two GAD isoforms differ in their enzyme activity and localization. GAD67 is primarily located in the cytoplasm, is constitutively active, and provides for the steady basal production of GABA, whereas GAD65 mainly is present in synaptic vesicles, undergoes auto-inactivation during enzyme activity, and occurs in the cell, providing for a pulse in production under circumstances that demand a rapid surge of GABA synthesis and release [14,18,19]. The two isoforms show high sequence similarity, with the middle and C-terminal domains having 74% identity but differing (25% identity) in the N-terminal domain, mainly in the first 100 amino acids [10,13,14].…”
Section: Introductionmentioning
confidence: 99%